NASDAQ:ALPN
Alpine Immune Sciences Inc Stock News
$38.65
+1.20 (+3.20%)
At Close: Mar 27, 2024
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
04:30pm, Wednesday, 20'th Mar 2024
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
08:26pm, Monday, 18'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This compares to loss of $0.41 per share a y
Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript
07:24pm, Monday, 18'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
09:40am, Thursday, 14'th Mar 2024
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Monday, 11'th Mar 2024
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
04:30pm, Thursday, 07'th Mar 2024
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade)
05:10pm, Friday, 22'nd Dec 2023
Alpine Immune Sciences, Inc. stock has increased by 176% since early coverage, driven by positive data from the basket study RUBY-3. Low-dose povetacicept showed meaningful improvements in disease bio
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 18'th Dec 2023
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
12:02pm, Monday, 11'th Dec 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
11:19am, Wednesday, 29'th Nov 2023
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?
11:17am, Monday, 30'th Oct 2023
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher
Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:32pm, Monday, 23'rd Oct 2023
Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for October 23rd
08:16am, Monday, 23'rd Oct 2023
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling
03:31pm, Friday, 06'th Oct 2023
Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology Annual Kidney Week Meeting in November 2023. The st